Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Li, Abby
S-CitAD, NCT03108846: Escitalopram for Agitation in Alzheimer's Disease	Active, not recruiting	3	187	Canada, US	Escitalopram, Lexapro, Placebo, non-applicable	JHSPH Center for Clinical Trials, National Institute on Aging (NIA)	Dementia	03/24	05/25
NAB-IT, NCT04516057: Nabilone for Agitation Blinded Intervention Trial	Recruiting	3	112	Canada	Nabilone, Cesamet, Placebo	Sunnybrook Health Sciences Centre, Alzheimer's Drug Discovery Foundation, Weston Brain Institute	Alzheimer Disease, Agitation	10/25	10/25
NCT04958031: A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy	Active, not recruiting	2	75	Canada, US	CVL-871 1.0 mg, CVL-871 3.0 mg, Placebo	Cerevel Therapeutics, LLC	Apathy in Dementia	01/25	02/25
Slow, Elizabeth
TEMPO-1, NCT04201093 / 2019-002949-38: Fixed-Dose Trial in Early Parkinson's Disease (PD)	Completed	3	522	Europe, Canada, US, RoW	Tavapadon, PF-06649751, CVL-751, Placebo	Cerevel Therapeutics, LLC	Parkinson Disease	06/24	06/24